Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage
- Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles -
- New data on MM-II to be presented this weekend at the OARSI 2025 World Conference on Osteoarthritis -
- MM-II recently granted Fast Track Designation by the US FDA -
MUMBAI, India and TEL AVIV, Israel, April 24, 2025 /PRNewswire/ -- Sun Pharma (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715) (Sun Pharmaceutical Industries Limited, and includes its subsidiaries or associate companies) and Israel-based Moebius Medical Limited announced today the publication of two articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI), highlighting MM-II, a novel non-opioid product for the treatment of symptomatic knee osteoarthritis.
MM-II is based on a proprietary suspension of large, empty, multilamellar liposomes designed to reduce joint friction and wear, thereby alleviating pain. The two publications offer complementary insights into MM-II's clinical efficacy and mechanism of action, underscoring its potential therapeutic value.
The first publication presents results from a Phase 2b randomized, double-blind, placebo-controlled trial (NCT04506463), which enrolled 397 patients across the US, Europe and Asia. Findings demonstrate that a single injection of MM-II provided clinically meaningful pain relief through 26 weeks, with a favorable safety and tolerability profile [Link: https://www.oarsijournal.com/article/S1063-4584(25)00975-6/fulltext ].
The second publication, titled " Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating," details MM-II's unique mechanism of action. The research shows that MM-II forms a lubricative layer over cartilage surfaces, reducing friction and slowing cartilage degeneration. The authors suggest that the results of the clinical trial may be mediated through the coating of the cartilage surfaces, though additional mechanisms may contribute to the long term pain reduction seen in Phase 2b study. [Link: https://doi.org/10.1016/j.joca.2025.02.774 ].
" The data from these publications show that MM-II has the potential to provide durable pain relief for patients," said Prof. Thomas J Schnitzer, MD, PhD, a rheumatologist and professor of Medicine at Northwestern University and lead author of the clinical trial manuscript. "With limited treatment options, lack of novel treatment approaches, and concerns around opioid use, MM-II may offer a promising alternative to hyaluronic acid and steroid treatments."
Moshe Weinstein, CEO of Moebius Medical, added:"Having both our clinical data and our research on MM-II's underlying mechanism of action published in the leading peer-reviewed journal for osteoarthritis further validates MM-II's novel treatment approach."
Coinciding with these publications, Sun Pharma and Moebius Medical are also presenting new data at the OARSI 2025 World Congress on Osteoarthritis taking place this week. Three abstracts were accepted for presentation at the congress, and the companies will also host a satellite symposium which exploring MM-II's mechanism of action, clinical data and planned phase 3 program.
About Osteoarthritis
Osteoarthritis is one of the most common chronic health conditions and a leading cause of pain and disability among adults. Global estimates reveal that more than 100 million people are affected by osteoarthritis. More than 20 million people in the US suffer from knee osteoarthritis. The global market for products used for symptomatic relief of knee osteoarthritis pain, including intra-articular hyaluronic acid and others, is estimated at $2 billion with a 6.5% compound annual growth rate. The US alone accounts for approximately 40% of this market.
About Moebius Medical
Moebius Medical is a clinical stage biotechnology company that is developing novel pain relief treatments for osteoarthritis. The company was founded in 2008 within the RAD Biomed Accelerator to develop products based on a patent-protected technology exclusively licensed from Yissum, the Hebrew University Technology Transfer Company; T3, the Technology Transfer arm of the Technion Institute; and by Hadasit, the Technology Transfer company of Hadassah Medical Center. In 2016, Moebius formed a joint collaboration with Sun Pharma in which Moebius is responsible for conducting certain preclinical studies and for product development and manufacturing through the end of Phase 2 studies, at which point Sun has the option to assume further product development and commercialization.
About Sun Pharmaceutical Industries Ltd. (CIN – L24230GJ1993PLC019050)
Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).
Disclaimer: Statements in this "document" describing Sun Pharma's and/or Moebius Medical's objectives, projections, estimates, expectations, plans or predictions, industry conditions, or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. Neither Sun Pharma nor Moebius Medical undertakes any obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
4 hours ago
- Korea Herald
S. Korea-China-Japan cooperation crucial as ‘buffer' as Trump 2.0 roils Asia
APEC summit will serve as springboard for bolstering trilateral coordination, observers say Trilateral cooperation among South Korea, China and Japan has become more essential than ever as a buffer in Northeast Asia fraught with mounting volatility and uncertainty under US President Trump's second term, former high-ranking officials and experts said. Observers from the three countries held the view that Northeast Asia has become the central battleground in the intensifying great-power rivalry between the US and China during a forum hosted by the North-East Asia Research Foundation, a Seoul-based think tank, on Monday. Chung Duck-koo, former minister of trade, industry and energy, underscored that 'further strengthening trilateral relations among South Korea, China and Japan would be highly beneficial,' as Northeast Asia sits at the fault line between the North Korea–China–Russia bloc and South Korea–US–Japan cooperation. 'As a group that intersects both triangular frameworks, our cooperation could serve as a bridge for promoting shared prosperity and safety,' Chung, who serves as the founder and incumbent chair of the NEAR Foundation, said in his opening speech during the forum "The Trump 2.0 Era and its Implications on Northeast Asia." "Such efforts could help ease or neutralize tensions and mitigate sources of conflict in the region." Kim Sung-han, a former national security adviser in the previous Yoon Suk Yeol administration, underscored that "the geopolitical confrontation between North Korea–China–Russia alignment and the ROK–US–Japan partnership is likely to intensify further." The ROK stands for the Republic of Korea, the official name of South Korea. Kim elucidated that the US has been doubling down on its strategic pivot to the Indo-Pacific region from Europe, setting the termination of the war in Ukraine in sight, while curtailing its military engagement in the Middle East. At the same time, China is expected to bolster its strategic partnership with Russia while reinvigorating ties with North Korea. 'In this context, trilateral cooperation among ROK, China and Japan becomes increasingly important to help ease regional tensions and prevent further polarization,' commented Kim, who currently serves as a professor of the Graduate School of International Studies at Korea University. Kim further explained, 'Trump 2.0's foreign policy is likely to push the Northeast Asian order toward a binary confrontation, which could weaken the strategic foundation for trilateral cooperation among ROK, China and Japan." 'Paradoxically, however, in the face of rising tensions, pragmatic and interest-based cooperation among those three countries may become even more necessary,' Kim said. 'As a result, Korea-China-Japan trilateral cooperation could serve as a 'diplomatic shock absorber' that helps ease geopolitical tensions and maintain regional equilibrium.' In his keynote address, Yun Byung-se, former foreign minister under the Park Geun-hye administration, said, 'Dialogue, exchanges and cooperation among South Korea, China and Japan are extremely valuable assets, amid the seismic geopolitical and geoeconomic shifts.' Observers also concurred that the North Korean nuclear challenge underscored the need for tighter Korea-China-Japan cooperation. Yun pointed out that 'North Korea will negotiate from its most advantageous strategic position since the Korean War' if a summit between Trump and North Korean leader Kim Jong-un materializes. 'Depending on the result, another shock may come to the landscape of Northeast Asia,' Yun said. 'Prior coordination between South Korea and the US, and among South Korea, the US and Japan, as well as close consultation with China, will be necessary.' Voicing similar views, Hitoshi Tanaka, former deputy foreign minister in Japan, also underscored that 'especially on pressing issues such as North Korea's nuclear program, close trilateral coordination is imperative.' Observers said this year's Asia-Pacific Economic Cooperation summit — set for late October to early November in Gyeongju, North Gyeongsang Province — will provide a valuable venue to advance trilateral cooperation. 'We understand China's sensitivity regarding Taiwan,' Tanaka said. 'However, just as APEC clearly separates political and security matters, including Taiwan in such frameworks should be considered to demonstrate that economic cooperation can transcend political divides.' The APEC summit will invite leaders from 21 countries in the Indo-Pacific region, including South Korea, the US, China, Japan and Taiwan. 'We hope that the leaders of our three countries — South Korea, China and Japan — will also take advantage of this opportunity to engage in meaningful dialogue,' Chung of the NEAR Foundation said. 'Regardless of the challenges that may arise, South Korea, China and Japan should aim to be in the same boat and remain committed to discussing any issue in depth. In this regard, we must not make the mistake of allowing the past to hinder the future,' Chung added.
Korea Herald
5 hours ago
- Korea Herald
Samsung Bioepis partners with Nipro for Japan market entry
Samsung Bioepis, the biosimilar unit of Samsung Group, announced Monday that it has signed a commercialization agreement with Japan-based pharmaceutical and medical device company Nipro to enter the Japanese market. The deal covers the licensing, development and commercialization of multiple biosimilars, including SB17, a biosimilar referencing Stelara (ustekinumab), used to treat autoimmune conditions. This marks the company's first partnership with a Japanese pharmaceutical company. Under the agreement, Samsung Bioepis will oversee development, manufacturing and supply, while Nipro will manage sales and distribution in Japan. 'The partnership is a major milestone for our entry into Japan,' said Samsung Bioepis CEO Kim Kyung-ah. 'We aim to enhance patient access to high-quality biopharmaceuticals through close collaboration with local partners.' SB17 is a biosimilar to Janssen's Stelara, which treats inflammatory diseases such as psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. Samsung Bioepis launched its proprietary Stelara biosimilar, Pyzchiva, in the US earlier this year, followed by an increased market competition after Stelara's US patent expiry in 2023. After receiving approval in Europe last year, Pyzchiva went on to secure a 43 percent market share, emerging as a leading product in the region's biosimilar market. Founded in 2012, Samsung Bioepis has gained approval for 11 blockbuster biosimilar products and posted 1.54 trillion won ($1.13 billion) in revenue in 2024. Meanwhile, Samsung Bioepis is scheduled to separate from its parent company, Samsung Biologics, in October to operate as a new holding company, a strategic move aimed at easing client concerns over potential conflicts of interest between Samsung Biologics' contract development and manufacturing business and Samsung Bioepis' biosimilar unit.
Korea Herald
3 days ago
- Korea Herald
Tesla tops monthly imported car sales for 1st time in Korea
Tesla has claimed the top spot in monthly imported car sales in the South Korean market for the first time. According to data from the Korea Automobile Importers & Distributors Association on Friday, the US-based electric vehicle powerhouse sold 6,570 units in May, a 57.7 percent increase compared to the previous year. It outpaced Mercedes-Benz's 6,415 units and BMW's 6,405 units. The two German carmakers have traditionally dominated the top two positions in South Korea's imported car sector. Porsche and Lexus secured fourth and fifth places, selling 1,192 units and 1,134 units, followed by Volvo's 1,129 units in the same period. Tesla's stellar performance was driven by the strong demand for the newly launched Model Y. Released in April, this new flagship mid-size SUV sold 4,961 units, accounting for 94.9 percent of Tesla's sales. The Model Y Long Range, boasting approximately 500 kilometers driving range — 100 kilometers longer than the standard model — also sold 1,276 units. The EV maker's robust sales have partly boosted the overall domestic imported car market. Last month's imported car sales reached 28,189 units, marking a 16.4 percent increase from last year. The cumulative sales from January to May rose by 10 percent, totaling 100,352 units. 'The rise in new registrations of imported passenger cars in May can be attributed to a steady supply from certain brands and the impact of new model launches,' stated KAIDA Vice Chairman Jung Yoon-young. Although Jung did not specify Tesla as the key contributor, figures show Tesla's two Model Y variants were named as the first and third best-selling models, respectively. Industry insiders point to Tesla focusing its supply on Korea, which has likely led to a sales boost, amid global declines. From January to April, the company saw sales drops of 34.6 percent in Europe and 9.1 percent in North America.
